Literature DB >> 9179380

Characterization of nociceptin hyperalgesia and allodynia in conscious mice.

N Hara1, T Minami, E Okuda-Ashitaka, T Sugimoto, M Sakai, M Onaka, H Mori, T Imanishi, K Shingu, S Ito.   

Abstract

1. Intrathecal (i.t.) administration of nociceptin and high doses of morphine induced allodynia in response to innocuous tactile stimuli, and i.t. nociceptin evoked hyperalgesia in response to noxious thermal stimuli in conscious mice. Here we have characterized the nociceptin-induced allodynia and compared it with the morphine-induced allodynia and the nociceptin-evoked hyperalgesia. 2. Nociceptin-induced allodynia was evoked by the first stimulus 5 min after i.t. injection, reached a maximum at 10 min, and continued for a 50 min experimental period. Dose-dependency of the allodynia showed a bell-shaped pattern from 50 pg to 5 ng kg-1, and the maximum effect was observed at 2.5 ng kg-1. 3. Morphine-induced allodynia reached the maximum effect at 15 min and declined progressively until cessation by 40-50 min. The dose-response curve showed a bell-shaped pattern, similar to that induced by nociceptin, with a maximum effect at 0.5 mg kg-1, five orders of magnitude higher than that of nociceptin. 4. The allodynia evoked by nociceptin and morphine were dose-dependently blocked by glycine, D(-)-2-amino-5-phosphonovaleric acid (D-AP5, an N-methyl-D-aspartate (NMDA) receptor antagonist), gamma-D-glutamylaminomethyl sulphonic acid (GAMS, a non-NMDA receptor antagonist) and methylene blue (a soluble guanylate cyclase inhibitor), but were not affected by muscimol (a gamma-aminobutyric acidA (GABAA) receptor agonist) and baclofen (a GABAB receptor agonist). 5. Morphine did not inhibit forskolin-stimulated cyclicAMP formation in cultured cells expressing the nociceptin receptor. 6. Nociceptin-induced hyperalgesia was evoked 10-15 min after i.t. injection. Nociceptin produced a monophasic hyperalgesic action over a wide range of doses from 5 fg to 50 ng kg-1. The nociceptin-induced hyperalgesia was blocked by glycine only among the agents examined. 7. None of the pain responses evoked by nociceptin and morphine were blocked by naloxone. 8. These results demonstrate that, whereas the mechanisms of the nociceptin-induced allodynia and hyperalgesia are evidently distinct, they involve a common neurochemical event beginning with the disinhibition of the inhibitory glycinergic response. Morphine may induce allodynia through a pathway common to nociceptin, but the nociceptin receptor does not mediate the action of high doses of morphine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179380      PMCID: PMC1564702          DOI: 10.1038/sj.bjp.0701146

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Nociceptin-induced scratching, biting and licking in mice: involvement of spinal NK1 receptors.

Authors:  T Sakurada; S Katsuyama; S Sakurada; M Inoue; K Tan-No; K Kisara; C Sakurada; H Ueda; J Sasaki
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Effects of nociceptin and nocistatin on antidromic vasodilatation in hairless skin of the rat hindlimb in vivo.

Authors:  H Häbler; L Timmermann; J Stegmann; W Jänig
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 3.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Nociceptin and the ORL-1 ligand [Phe1psi (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain.

Authors:  R Bertorelli; L Corradini; K Rafiq; J Tupper; G Calò; E Ongini
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

5.  Nociceptin (1 - 7) antagonizes nociceptin-induced hyperalgesia in mice.

Authors:  T Sakurada; S Sakurada; S Katsuyama; C Sakurada; K Tan-No; L Terenius
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

6.  Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.

Authors:  N Zaveri; W E Polgar; C M Olsen; A B Kelson; P Grundt; J W Lewis; L Toll
Journal:  Eur J Pharmacol       Date:  2001-09-28       Impact factor: 4.432

7.  Intrinsic and synaptic long-term depression of NTS relay of nociceptin- and capsaicin-sensitive cardiopulmonary afferents hyperactivity.

Authors:  Armenak Bantikyan; Gang Song; Paula Feinberg-Zadek; Chi-Sang Poon
Journal:  Pflugers Arch       Date:  2008-08-14       Impact factor: 3.657

8.  On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data.

Authors:  Ronald J Tallarida; Alan Cowan; Robert B Raffa
Journal:  Drug Alcohol Depend       Date:  2010-01-12       Impact factor: 4.492

9.  [Regulation of spinal nociceptin expression by neuropathic pain].

Authors:  A Gabriel; C Pietruck; T Meuser; M Sharma; P Pierce Palmer; S Grond
Journal:  Anaesthesist       Date:  2004-07       Impact factor: 1.041

10.  In vitro and ex vivo effects of a selective nociceptin/orphanin FQ (N/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H]N/OFQ and [35S]GTPgammaS in rat brain and spinal cord.

Authors:  Shizuo Yamada; Toyofumi Kusaka; Akihiko Urayama; Ryohei Kimura; Yasuo Watanabe
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.